anti mouse igg3  (SouthernBiotech)

Journal: bioRxiv

Article Title: Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

doi: 10.64898/2026.03.01.708859

Figure Lengend Snippet: A) Experimental timeline of the immunisation (i.e., vaccination) against OVA and subsequent tumour inoculation of the OVA-expressing B16F10 cell lines in mice. B) Titers of anti-OVA IgG per IgG subtypes in the plasma of the mice at d18. C) Percentage of OVA-specific CD8 + T cells against the immunogenic epitope OVA 257-264 (SIINFEKL) in the blood at d18 in pre-immunised mice (vax) or naïve mice (no vax) (n ≥ 3, mean ± SD, unpaired t-test). D, E) B16F10 melanoma cells, either wild-type (WT) or genetically modified to express high ( HI ) or low ( LO ) doses of membrane-bound OVA (B16mOVA) or soluble OVA (B16-OVA), were injected intradermally in C57BL/6 mice. Tumour growth (D) and associated survival (E) of the different OVA-expressing B16 cell lines in pre-immunised mice (n ≥ 5, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d10, d14 or d26 for tumour growth, log-rank tests for survival). F) Potential anti-tumour mechanisms engaged by soluble (left) or membrane-bound (right) xenoantigens when expressed by cancer cells.

Article Snippet: Samples were applied to the antigen coated plate and incubated at RT for 2 h. The plates were washed three times with PBST and HRP-conjugated antibodies were used to detect antigen-specific antibodies: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from Southern Biotech (Birmingham, AL, USA).

Techniques: Expressing, Clinical Proteomics, Genetically Modified, Membrane, Injection

Journal: bioRxiv

Article Title: Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

doi: 10.64898/2026.03.01.708859

Figure Lengend Snippet: A) Immunofluorescent staining of B16F10 WT melanoma with the TRP1-targeting TA99 antibody (scale bar = 100 μm). B) B16F10 WT tumour growth upon treatment with TA99 or IgG2a isotype control (n ≥ 4, mean ± SEM, Mann-Whitney test on d11). C) Design of FabTRP-OVA fusion protein and analysis of its production by SDS-PAGE (expected size = 92,3 kDa). D) Illustration of the FabTRP-OVA fusion protein approach for targeting the xenoantigen to the cancer cell membrane. E) Representative flow cytometry plot of FabTRP-OVA, OVA and no OVA (i.e., secondary antibody only) binding to the surface of B16F10 WT cells. F) B16F10 WT tumour growth when treated with FabTRP-OVA in pre-immunised or naïve mice (n ≥ 4, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d12). G) B16F10 WT tumour growth when treated with FabTRP-OVA in combination with anti-PD-1 checkpoint blocade therapy (n ≥ 4, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d12). H) Experimental treatment timeline of xenoantigen delivery (i.e., FabTRP-OVA, OVA or PBS (vehicle only)) and anti-PD-1 checkpoint blockade therapy in B16F10 WT in mice pre-immunised against OVA (Vax) or naïve (No vax). I, J) B16F10 WT tumour growth (I) and associated mouse survival (J) upon treatment with FabTRP-OVA, OVA or PBS in combination with anti-PD-1 checkpoint blockade therapy (n ≥ 5, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d16, log-rank tests for survival).

Article Snippet: Samples were applied to the antigen coated plate and incubated at RT for 2 h. The plates were washed three times with PBST and HRP-conjugated antibodies were used to detect antigen-specific antibodies: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from Southern Biotech (Birmingham, AL, USA).

Techniques: Staining, Control, MANN-WHITNEY, SDS Page, Membrane, Flow Cytometry, Binding Assay

Journal: bioRxiv

Article Title: Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

doi: 10.64898/2026.03.01.708859

Figure Lengend Snippet: A) Experimental timeline of the immunisation (i.e., vaccination) against varicella VZVO using Varivax or a combination of gE/CpG. B) IFΝγ quantification in the supernatant of gE restimulated (+) or non-restimulated (-) splenocytes, collected from mice immunized with Varivax, gE/CpG or PBS (i.e., naïve). Ionomycin+PMA was used as a positive control. C) Titers of anti-gE total IgG and per IgG subtypes in the plasma of the pre-immunised mice at d55 (before tumour implantation). D) Experimental treatment timeline of xenoantigen delivery (i.e., Varivax, gE or PBS (vehicle only)) and anti-PD-1 checkpoint blockade treatment in B16F10 WT in mice pre-immunised with Varivax against varicella VZVO . E, F) B16F10 WT tumour growth (E) and associated mouse survival (F) upon treatment with Varivax, gE or PBS in combination with anti-PD-1 checkpoint blockade (n ≥ 7, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d16, log-rank tests for survival).

Article Snippet: Samples were applied to the antigen coated plate and incubated at RT for 2 h. The plates were washed three times with PBST and HRP-conjugated antibodies were used to detect antigen-specific antibodies: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from Southern Biotech (Birmingham, AL, USA).

Techniques: Positive Control, Clinical Proteomics

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: Comparison of the in vitro C3b and C4b complement depositions via spike (C3b(S) and C4b(S)) or nucleocapsid (C3b(N) and C4b(N)) recombinant proteins between patients with (Ab(+)) or without (Ab(-)) SARS-CoV-2-specific IgM and IgG antibodies from four different COVID-19 groups (CONV, HOSP, HOSP + O 2 and ICU). The in vitro C3b and C4b complement depositions were measured by our in-house complement deposition assays, where we used carrier free recombinant nucleocapsid or spike proteins and non-heat-inactivated patient sera. The p values for the pair-wise group comparisons on the violin plots were calculated by the Mann-Whitney tests. P values of significant differences are marked as p MW between without and with specific antibodies. Non-significant differences are marked as n.s.

Article Snippet: Mouse anti-human IgG3 Hinge-HRP (HP6050) , SouthernBiotech , 9210-05.

Techniques: Comparison, In Vitro, Recombinant, MANN-WHITNEY

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: Comparison of the levels of SARS-CoV-2-specific IgM and IgG among four COVID-19 groups (CONV, HOSP, HOSP + O2, ICU) measured by Generic Assays CoV-2 IgM or IgG ( a ). The percentages of SARS-CoV-2-specific IgG or IgM positivity were shown also for four different COVID-19 groups. The numbers represent the mean percentages of SARS-CoV-2-specific IgM in blue or specific IgG in green circle sectors ( b ). The levels of total S- or N-specific IgG were quantified by in-house ELISA, normalized to positive and negative serum samples ( c ). The levels of S-specific and N-specific IgG1 ( d ) and IgG3 ( e ) subclasses were quantified by in-house ELISA calibrated with purified human IgG1 and IgG3. The p -values ( p KW ) were determined by Kruskal-Wallis test.

Article Snippet: Mouse anti-human IgG3 Hinge-HRP (HP6050) , SouthernBiotech , 9210-05.

Techniques: Comparison, Enzyme-linked Immunosorbent Assay, Purification

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: The in vitro C3b and C4b complement depositions via spike (C3b(S) and C4b(S)) recombinant protein are plotted by the levels of S-specific IgG1 and IgG3 in CONV individuals and in the other three hospitalized COVID-19 groups (HOSP, HOSP + O 2 and ICU) ( a ). The in vitro C3b and C4b complement depositions via nucleocapsid (C3b(N) and C4b(N)) recombinant protein are plotted by the levels of N-specific IgG1 and IgG3 in CONV individuals and in the other three hospitalized COVID-19 groups (HOSP, HOSP + O 2 and ICU) ( b ).

Article Snippet: Mouse anti-human IgG3 Hinge-HRP (HP6050) , SouthernBiotech , 9210-05.

Techniques: In Vitro, Recombinant

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: Comparison of the levels of SARS-CoV-2-specific IgM and IgG antibodies, and in vivo complement profiles in all COVID-19 patients between low and high in vitro C3b(N) complement depositions. The p values for the pair-wise group comparisons on the violin plots were calculated by the Mann-Whitney tests. Asterisks indicate p value < 0.0143 , considered significant results after 5% FDR correction using the Benjamini-Hochberg method.

Article Snippet: Mouse anti-human IgG3 Hinge-HRP (HP6050) , SouthernBiotech , 9210-05.

Techniques: Comparison, In Vivo, In Vitro, MANN-WHITNEY

Journal: Vaccines

Article Title: Adjuvanted Protein Vaccines Boost RNA-Based Vaccines for Broader and More Potent Immune Responses

doi: 10.3390/vaccines13080797

Figure Lengend Snippet: Figure 2. Anti-SARS-CoV-2 antibody responses in mice immunized with spike protein + adjuvant. Mice were immunized with a SARS-CoV-2 D614G protein in combination with a specified adjuvant at days 0 (prime) and 28 (boost). (A) Anti-SARS-CoV-2 IgG endpoint titer values are presented in the graphs, against the indicated SARS-CoV-2 variant spike protein. The bars represent the mean values of endpoint titers with standard error bars. (B) Summary mean values of anti-SARS-CoV-2 titers against each variant are shown at day 56, the last time point when serum samples were collected. Table 2 shows the numeric values and standard error of the endpoint titers of antibody isotypes IgG1, IgG2c, IgG3, and total IgG against the SARS-CoV-2 D614G protein generated in response to immunization at day 56 post-immunization. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Isotype ELISAs were carried out identically to the above, except for the use of the following secondary antibodies: goat anti-mouse IgG1 Human-adsorbed-HRP, goat antimouse IgG2a/IgG2c-HRP, or goat anti-mouse IgG3 Human-adsorbed HRP (Southern Biotech, Birmingham, AL, USA).

Techniques: Adjuvant, Variant Assay, Generated

Journal: Vaccines

Article Title: Adjuvanted Protein Vaccines Boost RNA-Based Vaccines for Broader and More Potent Immune Responses

doi: 10.3390/vaccines13080797

Figure Lengend Snippet: Figure 3. SARS-CoV-2 pseudovirus neutralization post-immunization with SARS-CoV-2 spike protein and adjuvant. After a prime and boost of SARS-CoV-2 D614G spike protein + indicated adjuvant on days 0 and 28, respectively, serum samples were taken at days 14, 28, and 56. Serum samples were tested for pseudovirus neutralization capabilities, with the mean IC50 values presented against (A) D614G spike- and (B) Omicron BA.1 spike-expressing pseudoviruses. Bars indicate mean IC50 values as calculated according to the methods. Saline (Group 1) resulted in all values below the limit of detection for pseudoneutralization. Pseudoneutralization IC50 values were correlated with the IgG endpoint titers, as presented in Figure 2, for (C) D614G and (D) Omicron BA.1 spike protein or pseudovirus, respectively. All pairs of pseudovirus neutralization IC50 and IgG endpoint titers were plotted and fit to a log–log linear regression to determine the goodness of fit and significance of correlation. † All values in group were below limit of detection. * p < 0.05, ** p < 0.01, **** p < 0.0001.

Article Snippet: Isotype ELISAs were carried out identically to the above, except for the use of the following secondary antibodies: goat anti-mouse IgG1 Human-adsorbed-HRP, goat antimouse IgG2a/IgG2c-HRP, or goat anti-mouse IgG3 Human-adsorbed HRP (Southern Biotech, Birmingham, AL, USA).

Techniques: Neutralization, Adjuvant, Expressing, Saline

Journal: Vaccines

Article Title: Adjuvanted Protein Vaccines Boost RNA-Based Vaccines for Broader and More Potent Immune Responses

doi: 10.3390/vaccines13080797

Figure Lengend Snippet: Figure 4. Anti-SARS-CoV-2 antibody response in mice immunized with multimodal spike protein and/or RNA in combination with adjuvant. Mice were immunized with the indicated regimen at days 0 (prime) and 42 (boost). Serum was tested for IgG responses against (A–C) D614G, (D–F) Delta P1, or (G–I) Omicron BA1 spike protein in an anti-SARS-CoV-2 IgG ELISA. Bars indicate mean IgG endpoint titer values with standard error bars. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Isotype ELISAs were carried out identically to the above, except for the use of the following secondary antibodies: goat anti-mouse IgG1 Human-adsorbed-HRP, goat antimouse IgG2a/IgG2c-HRP, or goat anti-mouse IgG3 Human-adsorbed HRP (Southern Biotech, Birmingham, AL, USA).

Techniques: Adjuvant, Enzyme-linked Immunosorbent Assay